Zevra Therapeutics Inc (ZVRA) Stock Price, Quote & News

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug pro...

Industry: Biotechnology

Sector: Healthcare

Phone: 321 939 3416

Website: zevra.com

Address:

1180 Celebration Boulevard, Suite 103, Celebration, United States

KemPharm_rocks Jul. 14 at 2:03 AM

$ZVRA The two conferences concluded. Hope they went well 👏🏻.

0 · Reply

KemPharm_rocks Jul. 13 at 7:39 PM

$ZVRA Interesting Sunday AI reads on Celiprolol:

2 · Reply

Pomer_Gile1 Jul. 13 at 6:19 PM

$ZVRA Does anyone have any revenue numbers for Celiprolol in Europe? Can’t seem to find anything concrete an AI didn’t help

2 · Reply

Papermoon347 Jul. 13 at 3:58 PM

$ZVRA That mad dash to buy into the close in the final few minutes was a thing of beauty to watch ,hopefully we continue tomorrow!

0 · Reply

OldManLogan Jul. 13 at 2:59 PM

$ZVRA No one knows anything for sure... but 1) Zevra would be a highly attractive franchise to a variety of mid to large cap pharma companies especially given the ability to ramp sales quickly with Miplyffa; ... yes but why now? 2) the sharp upward move with heavy volume on essentially no news and the big, big bets in ZVRA call options suggest that the company could be in play sooner rather than later.

3 · Reply

billymike Jul. 13 at 2:26 PM

$ZVRA is this BO talk real?

3 · Reply

KemPharm_rocks Jul. 13 at 12:25 PM

$ZVRA 🍾🍾🍾🍾🍾

0 · Reply

farcanal Jul. 13 at 10:20 AM

$ZVRA 🥂

2 · Reply

Smedley1 Jul. 13 at 12:30 AM

$ITRM ive got such a hard on for this and $ZVRA right now…with Zevra being my conservative play with 20k shares…cant miss to at least $25….and Iterum being my speculative play with 100k shares…hell yes, lets go !!!!!!!

0 · Reply

MarkTheGenius Jul. 12 at 11:58 PM

$ZVRA Papermoon...Yes, we got a player thats been going Gordon Gekko with calls. We can assume 2 things. Either... 1. He knows something and is placing a large bet. 2. Something is going to happen within 1-2 months. So, just hold your stock and calls and roll the dice. Stay relaxed, dont get emotional. We got an over Bullish board and normally I don't like that. I'm making an exception with ZVRA.

2 · Reply

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 21, 2025, 7:30 AM EDT - 7 weeks ago

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 13, 2025, 10:45 PM EDT - 2 months ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:30 AM EDT - 2 months ago

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

Apr 17, 2025, 7:30 AM EDT - 3 months ago

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

Apr 7, 2025, 7:30 AM EDT - 3 months ago

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Mar 31, 2025, 4:12 PM EDT - 3 months ago

Zevra Therapeutics Files Preliminary Proxy

Mar 11, 2025, 8:16 PM EDT - 4 months ago

Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 4:05 PM EDT - 4 months ago

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Feb 28, 2025, 7:30 AM EST - 4 months ago

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Feb 27, 2025, 7:30 AM EST - 4 months ago

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Feb 26, 2025, 9:46 AM EST - 4 months ago

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

Feb 24, 2025, 4:02 PM EST - 4 months ago

Zevra to Participate at Upcoming Investor Conferences

Jan 30, 2025, 7:30 AM EST - 5 months ago

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

Jan 29, 2025, 4:05 PM EST - 5 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Jan 8, 2025, 11:13 AM EST - 6 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MDGL MRK

Dec 17, 2024, 7:30 AM EST - 7 months ago

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

Dec 6, 2024, 5:00 PM EST - 7 months ago

Zevra Therapeutics Announces Organizational Changes

Nov 21, 2024, 4:51 PM EST - 8 months ago

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Nov 13, 2024, 7:12 AM EST - 8 months ago

Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:36 PM EST - 8 months ago

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

Nov 6, 2024, 7:30 AM EST - 8 months ago

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

Oct 31, 2024, 7:30 AM EDT - 9 months ago

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Oct 10, 2024, 7:30 AM EDT - 9 months ago

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Sep 24, 2024, 7:30 AM EDT - 10 months ago

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

Sep 20, 2024, 12:08 PM EDT - 10 months ago

Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

Sep 20, 2024, 10:14 AM EDT - 10 months ago

US FDA approves Zevra's genetic disorder treatment

Sep 6, 2024, 8:30 AM EDT - 11 months ago

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Aug 13, 2024, 9:45 PM EDT - 11 months ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 12:00 AM EDT - 1 year ago

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

Aug 7, 2024, 9:34 AM EDT - 1 year ago

Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference

Aug 2, 2024, 5:50 PM EDT - 1 year ago

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

Jul 30, 2024, 8:38 AM EDT - 1 year ago

Zevra Therapeutics to Report Second Quarter 2024 Financial Results

Jun 25, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Expands Executive Leadership Team

Jun 18, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

Jun 3, 2024, 11:00 AM EDT - 1 year ago

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

May 8, 2024, 2:53 PM EDT - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

May 1, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024

Apr 29, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

Apr 15, 2024, 5:01 PM EDT - 1 year ago

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

Apr 10, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility

Mar 28, 2024, 10:25 PM EDT - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 4:32 PM EDT - 1 year ago

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Mar 26, 2024, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Mar 25, 2024, 4:30 PM EDT - 1 year ago

Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 18, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024

Mar 4, 2024, 7:30 AM EST - 1 year ago

Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

KemPharm_rocks Jul. 14 at 2:03 AM

$ZVRA The two conferences concluded. Hope they went well 👏🏻.

0 · Reply

KemPharm_rocks Jul. 13 at 7:39 PM

$ZVRA Interesting Sunday AI reads on Celiprolol:

2 · Reply

Pomer_Gile1 Jul. 13 at 6:19 PM

$ZVRA Does anyone have any revenue numbers for Celiprolol in Europe? Can’t seem to find anything concrete an AI didn’t help

2 · Reply

Papermoon347 Jul. 13 at 3:58 PM

$ZVRA That mad dash to buy into the close in the final few minutes was a thing of beauty to watch ,hopefully we continue tomorrow!

0 · Reply

OldManLogan Jul. 13 at 2:59 PM

3 · Reply

billymike Jul. 13 at 2:26 PM

$ZVRA is this BO talk real?

3 · Reply

KemPharm_rocks Jul. 13 at 12:25 PM

$ZVRA 🍾🍾🍾🍾🍾

0 · Reply

farcanal Jul. 13 at 10:20 AM

$ZVRA 🥂

2 · Reply

Smedley1 Jul. 13 at 12:30 AM

0 · Reply

MarkTheGenius Jul. 12 at 11:58 PM

2 · Reply

Papermoon347 Jul. 12 at 9:08 PM

$ZVRA The buyer of those options not looking only for $13 ,I believe we might see $15 next week cause calls will be printing all week !

1 · Reply

Savatije Jul. 12 at 8:27 PM

$ZVRA

0 · Reply

RodRosenstein Jul. 12 at 7:24 PM

$ZVRA @GordonGekko888 Gordie there is only one true Rod.

5 · Reply

ekoostik16 Jul. 12 at 7:19 PM

$ZVRA July 14s had 259 volume Friday at .30. Even july 16s had 11 volume at .10.

1 · Reply

KemPharm_rocks Jul. 12 at 2:10 PM

$ZVRA I wonder whether AI believes that this upward trend will continue into next week?

0 · Reply

WaynD01 Jul. 12 at 1:27 PM

$ZVRA @Torn891 I do not think he is going for one. He has said before that his focus is on EU rather than acquiring something. Even if he tries, we have lot of dead cheap assets available in the market. As an example MDCX recently bought a company with two phase2b cancer assets for just $6M equivalent shares and no upfront payments -all payments are back loaded with milestones. Do not think ACER acquisition as a standard. I strongly suspect some malpractice by insiders happened there. Else even a Kindergarten would not buy it ( even for a much less price).

4 · Reply

KemPharm_rocks Jul. 12 at 1:27 PM

$ZVRA An oldy, but goody. Thanks Travis!

0 · Reply

intowits Jul. 12 at 1:12 PM

$ZVRA "Zevra Therapeutics was upgraded by research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Saturday."

1 · Reply

intowits Jul. 12 at 1:08 PM

$ZVRA FYI, this weeks volume summary: Mon 4,931,557 Tues 1,442,813 Weds 1,000,887 Thur 1,694,374 Fri 1,626,006 Total 10,395,637

2 · Reply

KemPharm_rocks Jul. 12 at 1:03 PM

$ZVRA So how you feeling about Zevra? 😊

0 · Reply

KemPharm_rocks Jul. 12 at 12:57 PM

$ZVRA Here’s a few examples of recent small-cap biotechs that, similar to Zevra, flew under the radar without attracting a lot of obnoxious Stocktwits chatter. As was pointed out, we’ve been quite lucky so far 🍀.

0 · Reply

WaynD01 Jul. 12 at 12:54 PM

$ZVRA The focus is being shifted to EMA. I believe, if this is not bought out in 6 months, it will be bought out by a EU company in max 12 months. Every big company likes to increase the bottom line. Hoarding cash wont help here. So holding shares for another 12 months, if not beyond, is a no brainer with almost no risk.

3 · Reply

Market Cap	685.14M
Revenue (ttm)	23.61M
Net Income (ttm)	-105.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	37.27
Profit Margin	-446.89%
Debt to Equity Ratio	1.46

Volume	1,626,600
Avg Vol	782,048
Day's Range	N/A - N/A
Shares Out	54.68M
Stochastic %K	100%
Beta	1.97
Analysts	Strong Sell
Price Target	$23.86